Venetoclax + Azacitidine
ApprovedActive 2 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Jan 6, 2022 → Mar 1, 2026
NCT ID
NCT05144243About Venetoclax + Azacitidine
Venetoclax + Azacitidine is a approved stage product being developed by AbbVie for Acute Myeloid Leukemia (AML). The current trial status is active. This product is registered under clinical trial identifier NCT05144243. Target conditions include Acute Myeloid Leukemia (AML).
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05144243 | Approved | Active |
| NCT04161885 | Phase 3 | Terminated |
| NCT02966782 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)